Cadrenal Therapeutics Inc. is a late-stage biopharmaceutical company focused on developing novel therapies for life-threatening immune and thrombotic conditions. Its lead program, CAD-1005, is a phase 3-ready, first-in-class 12-LOX inhibitor designed to treat heparin-induced thrombocytopenia (HIT), a severe immune-mediated thrombotic disorder, by targeting the primary underlying immune mechanisms unlike existing treatments that only address complications. CAD-1005 has received Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration, along with orphan drug status from the European Medicines Agency, and second-generation 12-LOX oral therapeutics are in development. The company's pipeline also features tecarfarin, a phase 3-ready oral vitamin K antagonist with a mechanism similar to warfarin but metabolized differently for potentially more reliable anticoagulation in patients with end-stage kidney disease and atrial fibrillation or those with left ventricular assist devices. Additionally, frunexian, a parenteral clinical-stage Factor XIa inhibitor, targets acute hospital settings, particularly complex cardiac surgeries involving medical devices. Cadrenal Therapeutics Inc. advances these investigational treatments to address unmet needs in critical care anticoagulation and immune disorders.